New antibiotics are urgently needed to combat persistent, emerging and re-emerging infectious diseases. Historically, microbial natural products have been a prolific source of antibacterials, and the screening of microbial extracts has yielded many classes of antibiotics. However, this approach was largely abandoned by big pharma because of the high rates of rediscovery of known antibiotics, and t ...